Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation.

Glucagon-like peptide-1 (GLP-1) agonists, originally developed as a treatment for type 2 diabetes, have been increasingly shown to demonstrate benefits for patients within the realm of cardiovascular disease, such as patients with obesity and congestive heart failure. As rates of patients with these conditions climb, the prevalence of atrial fibrillation, one of the world's most common arrhythmias, has also increased. The goal of this literature review is to examine what, if any, links GLP-1 agonists may have in preventing or treating atrial fibrillation. To date, a number of meta-analyses have been conducted studying potential relationships between GLP-1 agonists and atrial fibrillation, but there has yet to be a randomized controlled trial fully exploring GLP-1's effects on atrial fibrillation.